Date: 2016-07-28
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Boehringer Ingelheim (Germany)
Product: BI 695501 (biosimilar version of Humira® (adalimumab))
Action mechanism: biosimilar/monoclonal antibody/TNF alpha inhibitor
Disease: psoriasis
Therapeutic area: Autoimmune diseases - Dermatological diseases
Country: Czech Republic, Estonia, Germany, Poland, Russian Federation, Slovakia, Ukraine, USA
Trial details: This randomized, double-blind, parallel-arm, multiple-dose, active comparator trial is evaluating the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis. (NCT02850965)
Latest
news:
